FOXP3 and type 1 diabetes mellitus: Consistent with this, BL001‐treated mDCs facilitated the expansion of an autologous Foxp3+/CD4+ regulatory T‐cell subpopulation while simultaneously inhibiting the proliferation of the global CD4+ and CD8+ cytotoxic T‐cells in individuals with T1D (Figure 5N,O).